1. Targeting BCL-2 in Hematologic Malignancies

   • Nadia Khan
   • Brad Kahl

   Review Article 08 March 2018 Pages: 257 - 267

   

2. Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease

   • Maximilian Hochmair

   Review Article Open access 27 April 2018 Pages: 269 - 285

   

3. Antibody–Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review

   • Cédric Rossi
   • Marie-Lorraine Chrétien
   • René-Olivier Casasnovas

   Review Article 20 March 2018 Pages: 287 - 308

   

4. Prognostic and Predictive Factors for Renal Cell Carcinoma

   • Cristina Suárez
   • Marc Campayo
   • Enrique Gallardo

   Review Article 22 March 2018 Pages: 309 - 331

   

5. The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review

   • Federico Nichetti
   • Antonio Marra
   • Sara Pusceddu

   Review Article 14 April 2018 Pages: 333 - 351

   

6. Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent Therapies

   • Pedro C. Barata
   • Dhrmesh Gopalakrishnan
   • Petros Grivas

   Original Research Article 06 April 2018 Pages: 353 - 361

   

7. The Impact of Dose and Simultaneous Use of Acid-Reducing Agents on the Effectiveness of Vemurafenib in Metastatic BRAF V600 Mutated Melanoma: a Retrospective Cohort Study

   • Lotte M. Knapen
   • Rutger H. T. Koornstra
   • Nielka P. van Erp

   Original Research Article Open access 11 April 2018 Pages: 363 - 370

   

8. Association of Expression Levels or Activation Status of STAT3 with Treatment Outcomes of Sunitinib in Patients with Renal Cell Carcinoma

   • Kazuhiro Yamamoto
   • Takuto Hara
   • Ikuko Yano

   Original Research Article 09 April 2018 Pages: 371 - 378

   

9. Prognostic Impact of the Components of Progressive Disease on Survival After First-Line Tyrosine Kinase Inhibitor Therapy for Metastatic Renal Cell Carcinoma

   • Takashi Ikeda
   • Hiroki Ishihara
   • Kazunari Tanabe

   Original Research Article 21 May 2018 Pages: 379 - 387

   

10. Discovery of a Potent and Mutant-Selective EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Lung Cancer

    • Dong Ha Kim
    • Yun Jung Choi
    • Jae Cheol Lee

    Original Research Article 12 May 2018 Pages: 389 - 398

    

11. Atezolizumab: A Review in Previously Treated Advanced Non-Small Cell Lung Cancer

    • Hannah A. Blair

    Adis Drug Evaluation 21 May 2018 Pages: 399 - 407

    

12. Avelumab: A Review in Metastatic Merkel Cell Carcinoma

    • Matt Shirley

    Adis Drug Evaluation 24 May 2018 Pages: 409 - 416